<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>MarylandReporter.com</provider_name><provider_url>https://marylandreporter.com</provider_url><title>Armistice Capital, RTW Investments, and Wellington Management Expand Rare Disease Therapeutics Holdings - MarylandReporter.com</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="bgsKv4CF1U"&gt;&lt;a href="https://marylandreporter.com/2025/08/04/armistice-capital-rtw-investments-and-wellington-management-expand-rare-disease-therapeutics-holdings/"&gt;Armistice Capital, RTW Investments, and Wellington Management Expand Rare Disease Therapeutics Holdings&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://marylandreporter.com/2025/08/04/armistice-capital-rtw-investments-and-wellington-management-expand-rare-disease-therapeutics-holdings/embed/#?secret=bgsKv4CF1U" width="600" height="338" title="&#x201C;Armistice Capital, RTW Investments, and Wellington Management Expand Rare Disease Therapeutics Holdings&#x201D; &#x2014; MarylandReporter.com" data-secret="bgsKv4CF1U" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://marylandreporter.com/wp-content/uploads/2025/08/jakub-zerdzicki-ip7GFn5JqX8-unsplash-1.jpg</thumbnail_url><thumbnail_width>640</thumbnail_width><thumbnail_height>427</thumbnail_height><description>Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have enlarged exposure to rare disease therapeutics companies as the orphan drugs market sustains robust growth momentum. Multiple specialized healthcare funds and broad-market asset managers deployed capital to the sector throughout 2024 and continue allocations in 2025, driven by accelerated FDA approvals and collaboration agreements [&hellip;]</description></oembed>
